GCP
OLMA icon

GSA Capital Partners’s Olema Pharmaceuticals OLMA Stock Holding History

GSA Capital Partners’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,268
Closed -$147K – 1958
2024
Q4 		$147K Buy
+25,268
New +$252K 0.01% 1474
2024
Q2 		– Sell
-27,013
Closed -$306K – 1926
2024
Q1 		$306K Sell
27,013
-17,227
-39% -$222K 0.02% 1206
2023
Q4 		$621K Sell
44,240
-15,533
-26% -$209K 0.05% 649
2023
Q3 		$738K Sell
59,773
-42,067
-41% -$429K 0.06% 563
2023
Q2 		$920K Sell
101,840
-128,792
-56% -$778K 0.09% 361
2023
Q1 		$800K Sell
230,632
-1,001
-0.4% -$4.08K 0.08% 439
2022
Q4 		$568K Buy
231,633
+127,549
+123% +$372K 0.07% 527
2022
Q3 		$287K Buy
+104,084
New +$441K 0.04% 962
2022
Q2 		– Sell
-72,287
Closed -$308K – 1690
2022
Q1 		$308K Buy
72,287
+32,060
+80% +$177K 0.04% 874
2021
Q4 		$377K Buy
+40,227
New +$833K 0.05% 784

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return

GSA Capital Partners's OLMA Position: Q1 2025 in Review

GSA Capital Partners sold out of Olema Pharmaceuticals (OLMA) in Q1 2025, closing a stake of 25,268 shares — an estimated $147K sold.

GSA Capital Partners first reported a position in OLMA in Q4 2021 and held it in 10 quarters. The position peaked at $920K in Q2 2023. 133 funds tracked by Wall St. Rank hold OLMA as of Q1 2025.

  • GSA Capital Partners reported no remaining Olema Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • GSA Capital Partners sold 25,268 Olema Pharmaceuticals shares in Q1 2025, an estimated $147K.
  • GSA Capital Partners first reported a position in Olema Pharmaceuticals in Q4 2021 and held it in 10 quarters.
  • GSA Capital Partners's Olema Pharmaceuticals position peaked at $920K in Q2 2023.
  • 133 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2025.

Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.